Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice
Executive Summary
The TRK inhibitor won over ASCO with deep and durable responses across 17 cancer types, but diagnostics will be the true test of the tumor-agnostic approach – and the focus of Loxo's commercial strategy.